These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 28708333)

  • 1. Conversion from calcineurin inhibitors to mTOR inhibitors as primary immunosuppressive drugs in pediatric heart transplantation.
    Asante-Korang A; Carapellucci J; Krasnopero D; Doyle A; Brown B; Amankwah E
    Clin Transplant; 2017 Oct; 31(10):. PubMed ID: 28708333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal function in heart transplant patients after switch to combined mammalian target of rapamycin inhibitor and calcineurin inhibitor therapy.
    Helmschrott M; Rivinius R; Bruckner T; Katus HA; Doesch AO
    Drug Des Devel Ther; 2017; 11():1673-1680. PubMed ID: 28652705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The change of immunosuppressive regimen from calcineurin inhibitors to mammalian target of rapamycin (mTOR) inhibitors and its effect on malignancy following heart transplantation.
    Saber-Moghaddam N; Nomani H; Sahebkar A; Johnston TP; Mohammadpour AH
    Int Immunopharmacol; 2019 Apr; 69():150-158. PubMed ID: 30711744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances in Mammalian Target of Rapamycin Inhibitor Use in Heart and Lung Transplantation.
    Fine NM; Kushwaha SS
    Transplantation; 2016 Dec; 100(12):2558-2568. PubMed ID: 27495747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR Inhibition and Clinical Transplantation: Heart.
    Zuckermann A; Osorio-Jaramillo E; Aliabadi-Zuckermann AZ
    Transplantation; 2018 Feb; 102(2S Suppl 1):S27-S29. PubMed ID: 29369971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion From Calcineurin Inhibitors to Mammalian Target-of-Rapamycin Inhibitors in Heart Transplant Recipients: A Meta-Analysis of Randomized Controlled Trials.
    Qiu Y; Wang X; Fan J; Rao Z; Lu Y; Lin T
    Transplant Proc; 2015 Dec; 47(10):2952-6. PubMed ID: 26707320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI.
    Sánchez-Escuredo A; Diekmann F; Revuelta I; Esforzado N; Ricart MJ; Cofán F; Torregrosa JV; Peri L; Ruiz Á; Campistol JM; Oppenheimer F
    Transpl Int; 2016 Mar; 29(3):362-8. PubMed ID: 26678359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome in heart transplant recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus.
    Fuchs U; Zittermann A; Ensminger SM; Schulz U; Gummert JF
    Transpl Immunol; 2014 Aug; 31(2):87-91. PubMed ID: 24932812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTOR inhibitors in pediatric liver transplant recipients.
    Dumortier J; Couchonnal E; Lacaille F; Rivet C; Debray D; Boillot O; Lachaux A; Ackermann O; Gonzales E; Wildhaber BE; Jacquemin E; McLin V
    Clin Res Hepatol Gastroenterol; 2019 Aug; 43(4):403-409. PubMed ID: 30528864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive function after heart transplantation: Comparing everolimus-based and calcineurin inhibitor-based regimens.
    Bürker BS; Gullestad L; Gude E; Relbo Authen A; Grov I; Hol PK; Andreassen AK; Arora S; Dew MA; Fiane AE; Haraldsen IR; Malt UF; Andersson S
    Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28185318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic Review on Role of Mammalian Target of Rapamycin Inhibitors as an Alternative to Calcineurin Inhibitors in Renal Transplant: Challenges and Window to Excel.
    Kumar J; Bridson JM; Sharma A; Halawa A
    Exp Clin Transplant; 2017 Jun; 15(3):241-252. PubMed ID: 27915965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid.
    Radtke J; Dietze N; Spetzler VN; Fischer L; Achilles EG; Li J; Scheidat S; Thaiss F; Nashan B; Koch M
    Transpl Infect Dis; 2016 Feb; 18(1):79-88. PubMed ID: 26707694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion From Calcineurin to Mammalian Target of Rapamycin Inhibitors in Liver Transplantation: A Meta-Analysis of Randomized Controlled Trials.
    Glover TE; Watson CJ; Gibbs P; Bradley JA; Ntzani EE; Kosmoliaptsis V
    Transplantation; 2016 Mar; 100(3):621-9. PubMed ID: 26636736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.
    Xie X; Jiang Y; Lai X; Xiang S; Shou Z; Chen J
    BMC Nephrol; 2015 Jul; 16():91. PubMed ID: 26126806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes associated with mammalian target of rapamycin (mTOR) inhibitors in heart transplant recipients: A meta-analysis.
    Jennings DL; Lange N; Shullo M; Latif F; Restaino S; Topkara VK; Takeda K; Takayama H; Naka Y; Farr M; Colombo P; Baker WL
    Int J Cardiol; 2018 Aug; 265():71-76. PubMed ID: 29605470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion from tacrolimus to sirolimus as a treatment modality in de novo allergies and immune-mediated disorders in pediatric liver transplant recipients.
    Kehar M; Grunebaum E; Jimenez-Rivera C; Mozer-Glassberg Y; Jamal A; Ng VL; Avitzur Y
    Pediatr Transplant; 2020 Sep; 24(6):e13737. PubMed ID: 32428390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation--8-year results.
    Guethoff S; Stroeh K; Grinninger C; Koenig MA; Kleinert EC; Rieger A; Mayr T; von Ziegler F; Reichart B; Hagl C; Schramm R; Kaczmarek I; Meiser BM
    J Heart Lung Transplant; 2015 May; 34(5):634-42. PubMed ID: 25701373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between circulating endothelial progenitor cell function and allograft rejection in heart transplant patients.
    Sathya CJ; Sheshgiri R; Prodger J; Tumiati L; Delgado D; Ross HJ; Rao V
    Transpl Int; 2010 Jun; 23(6):641-8. PubMed ID: 20102553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Recipients: One-Year Results of a Scandinavian Randomized Trial.
    Arora S; Andreassen AK; Andersson B; Gustafsson F; Eiskjaer H; Bøtker HE; Rådegran G; Gude E; Ioanes D; Solbu D; Sigurdardottir V; Dellgren G; Erikstad I; Solberg OG; Ueland T; Aukrust P; Gullestad L;
    Am J Transplant; 2015 Jul; 15(7):1967-75. PubMed ID: 25783974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term experience using CNI-free immunosuppression in selected paediatric heart transplant recipients.
    Rosenthal LM; Nordmeyer J; Kramer P; Danne F; Pfitzer C; Berger F; Schmitt KRL; Schubert S
    Pediatr Transplant; 2021 Dec; 25(8):e14111. PubMed ID: 34405495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.